MRE as a Screening Tool for axSpA in IBD

NCT ID: NCT03817983

Last Updated: 2025-01-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

259 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-04

Study Completion Date

2020-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the effectiveness (specificity and sensitivity) of using magnetic resonance enterography (MRE) as a screening tool for axial spondyloarthritis (axSpA) in patients with Crohns disease. Patients with evidence of axSpA on MRE imaging will be assessed clinically for axSpA (including a dedicated axial magnetic resonance imaging scan of the spine and sacroiliac joints) and will be compared to a group of age and sex-matched control participants with Crohn's disease but with no evidence of axSpA on MRE imaging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spondyloarthritis (SpA) is a term that encompasses psoriatic arthritis with axial disease, ankylosing spondylitis and non-radiological axial spondyloarthritis. The prevalence of SpA in the general population is estimated to be between 0.01%-2.5%. SpA patients have a high burden of inflammatory bowel disease (IBD), which primarily includes Crohn's disease (CD) and Ulcerative colitis (UC), with an estimated prevalence of 10%-12%. However, few studies have investigated the converse; the presence of IBD cases with undiagnosed SpA. Untreated SpA may lead to a significant impact on general health and quality of life; therefore early diagnosis and treatment is crucial. Most CD patients will have had a MRE assessment for their CD, which also captures the axial skeleton and can therefore be used to screen for evidence of axial SpA (axSpA). In this study, MRE images from consenting CD subjects will be reviewed for evidence of axSpA. CD patients with evidence of axSpA will then be reviewed in a rheumatology clinic to assess more specifically for SpA. This will include completion of patient reported outcome measures, clinical examination, routine blood tests, human leucocyte antigen (HLA)-B27 genotyping and a dedicated axial magnetic resonance imaging (MRI) scan. The patients will also be consented to participate in the second part of the study which will be to compare these 'cases' statistically to a 'control' group of age- and sex-matched CD subjects without MRE evidence of axSpA.

This study aims to: (i) determine the validity, sensitivity and specificity of MRE as a screening tool for axSpA in CD patients using dedicated axial MRI scans with clinical assessment as the gold standard; (ii) devise an algorithm of clinical indices that can be used as a screening tool for axSpA in CD cases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Axial Spondyloarthritis Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ProSpA-CD Screen Phase: MRE review for axSpA

Review of MRE scan for evidence of axSpA in Crohn's disease patients

MRE review for evidence of axSpA in SIJs

Intervention Type DIAGNOSTIC_TEST

Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease

ProSpA-CD Assess Phase (cases): Clinical assessment and dedicated MRI of the spine and pelvis

Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA for participants with abnormalities identified in the sacroiliac joints (SIJs) on MRE (cases).

Clinical assessment and dedicated MRI of the spine and pelvis

Intervention Type DIAGNOSTIC_TEST

Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA

ProSpA-CD Assess Phase (controls): Clinical assessment and dedicated MRI of the spine and pelvis

Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA for participants with normal SIJs (controls) on MRE.

Clinical assessment and dedicated MRI of the spine and pelvis

Intervention Type DIAGNOSTIC_TEST

Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRE review for evidence of axSpA in SIJs

Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease

Intervention Type DIAGNOSTIC_TEST

Clinical assessment and dedicated MRI of the spine and pelvis

Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects who are willing and able to give informed consent for participation in the study.
2. Male and female subjects aged 18 years or above.
3. Diagnosed by the gastroenterology team with Crohn's disease.
4. MRE imaging since 2015 for their Crohn's disease.

Exclusion Criteria

1\. Subjects unwilling or unable to give informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jobie Evans

Dr Jobie Evans (MD Student)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deepak R Jadon, MBBCh PhD

Role: PRINCIPAL_INVESTIGATOR

CUH NHSFT

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rheumatology Research Unit

Cambridge, Cambridgeshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A094864

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Early MRI Prediction of Crohns
NCT03340519 COMPLETED
Ultrasound Evaluation of Crohn's Disease
NCT03235180 TERMINATED PHASE4